OUR LADY OF THE LAKE REGIONAL MEDICAL CENTER						
Policy Manual: Pha		armacy	Section:	Medication Use, Storage and Handling		
Title:	Orders: Sound alike look alike Drugs (SALADs)		Policy Reference #:	PH-23-08		
			Supersedes #:	РН-10-17-О		
Date of Origination:		05/23/2006	Last Date Reviewed:	09/28/2021		
Last Date Revised:		05/09/2018				

PURPOSE

To improve patient safety by using safeguards to reduce the potential for sound alike look alike medication errors

POLICY

Patient safety procedures will be in place to reduce the potential for a medication error related to prescribing, dispensing and administering medications with sound alike look alike names and/or packaging.

- For the purposes of Lake Physician Group (LPG) Clinics, please refer to policy NM021 Sound Alike Look Alike Medications. LPG areas are governed by a separate council and therefore may have a separate sound a like look a like approved drug list for LPG areas.
- LSU Health Baton Rouge Clinics may also use a more appropriate, clinic administered medication list of sound alike look alike medications similar to, if not the same as, the list used by LPG clinics. This list of medications is attached at the end of this policy.

•

PROCEDURE

One or more of the following strategies will be utilized for sound alike look alike medications:

- **Tall-Man Lettering**: Tall-man lettering will be utilized to differentiate products that have sound alike look alike names in the computer, automated dispensing devices, and in storage areas..
- **Storage:** Similar sound alike look alike products will be separated within the pharmacy, patient care areas, automated dispensing machines and other settings when possible.
- **Order Entry Enhancements:** Pop-up windows may be used during order entry to alert pharmacists and nurses of a potential sound a like look a like medication.
- **Maintain awareness** of sound alike look alike drug names by providing information to all department staff.
- Auxiliary labeling may be used as an alternate means of awareness and notification.
- The potential for Sound a like Look a like Drugs, as a cause of medication errors, will be reviewed by the Pharmacy and Therapeutics Committee at the time a medication is considered for formulary status.

• The list of Sound a like Look a like Drugs will be reviewed annually by the Pharmacy and Therapeutics Committee.

REFERENCES

MM 01.02.01 EP1. The Hospital develops a list of look-alike/sound-alike medications it stores, dispenses or administers.

MM 01.02.01 EP2. The Hospital takes action to prevent errors involving the interchange of the meds on its list of look-alike/sound-alike medications.

MM 01.02.01 EP3. The Hospital annually reviews and, as necessary, revises its list of look-alike/sound-alike medications.

MM 04.01.01 EP4. The hospital has a written policy that defines the precautions for ordering medications with look-alike or sound-alike names. *The Joint Commission Medication Management Standards*

ISMP Institute for Safe Medication Practices

FDA and ISMP Lists of Look-Alike Drug Names with Recommended Tall Man Letters

The look-alike drug names in the Tables that follow have been modified using tall man (mixed case) letters to help draw attention to the dissimilarities in their names. Several studies have shown that highlighting sections of drug names using tall man letters can help distinguish similar drug names,¹ making them less prone to mix-ups.²⁻³ ISMP, FDA, The Joint Commission, and other safety-conscious organizations have promoted the use of tall man letters as one means of reducing confusion between similar drug names.

Table 1 provides an alphabetized list of FDA-approved established drug names with recommended tall man letters, which were first identified during the FDA Name Differentiation Project (<u>www.fda.gov/Drugs/</u> <u>DrugSafety/MedicationErrors/ucm164587.htm</u>).

Table 2 provides an alphabetized list of additional drug names with recommendations from ISMP regarding the use and placement of tall man letters. This is not an official list approved by FDA. It is intended for voluntary use by healthcare practitioners and drug information vendors. Any product label changes by manufacturers require FDA approval.

One of the difficulties with the use of tall man letters includes inconsistent application in health settings and lack of standardization regarding which letters to present in uppercase. A new study by Gerrett⁴ describes several ways to determine which of the dissimilar letters in each drug name should be highlighted. To promote standardization, ISMP followed one of these tested methodologies whenever possible. Called the CD3 rule, the methodology suggests working from the left of the word first by capitalizing all the characters to the right once two or more dissimilar letters are encountered, and then, working from the right of the word back, returning two or more letters common to both words to lowercase letters. When the rule cannot be applied because there are no common letters on the right side of the word, the methodology suggests capitalizing the central part of the word only. ISMP suggests that the tall man lettering scheme provided in Tables 1 and 2 be followed when presenting these drug names to healthcare providers to promote consistency. At this time, scientific studies do not support the use of tall man letters when presenting drug names to patients.

References: 1) Filik R, Purdy K, Gale A, Gerrett D. Drug name confusion: evaluating the effectiveness of capital ("Tall Man") letters using eye movement data. *Social Science & Medicine* 2004;59(12):2597-2601. 2) Filik R, Purdy K, Gale A, Gerrett D. Labeling of medicines and patient safety: evaluating methods of reducing drug name confusion. *Human Factors* 2006;48(1):39-47. 3) Grasha A. Cognitive systems perspective on human performance in the pharmacy: implications for accuracy, effectiveness, and job satisfaction. Alexandria (VA): NACDS; 2000 Report No. 062100. 4) Gerrett D, Gale AG, Darker IT, Filik R, Purdy KJ. Tall man lettering. Final report of the use of tall man lettering to minimize selection errors of medicine names in computer prescribing and dispensing systems. Loughborough University Enterprises Ltd.; 2009 (www.connectingforhealth.nhs.uk/systemsandservices/eprescribing/refdocs/ tallman.pdf).

able 1. FDA-Approved List of Generic Drug Names with Tall Man Letters	
Drug Name with Tall Man Letters	Confused with
acetaZOLAMIDE	acetoHEXAMIDE
acetoHEXAMIDE	acetaZOLAMIDE
buPROPion	busPIRone
busPIRone	buPROPion
chlorproMAZINE	chlorproPAMIDE
chlorproPAMIDE	chlorproMAZINE
clomiPHENE	clomiPRAMINE
clomiPRAMINE	clomiPHENE
cycloSERINE	cycloSPORINE
cycloSPORINE	cycloSERINE
DAUNOrubicin	DOXOrubicin
dimenhyDRINATE	diphenhydrAMINE
diphenhydrAMINE	dimenhyDRINATE
DOBUTamine	DOPamine
DOPamine	DOBUTamine

continued on next page

© ISMP 2011. Permission is granted to reproduce material for internal newsletters or communications with proper attribution. Other reproduction is prohibited without written permission from ISMP. Report actual and potential medication errors to the Medication Errors Reporting Program (MERP) via the Web at www.ismp.org or by calling 1-800-FAIL-SAF(E).



Ismp Institute for	Safe Medication Practices					
FDA and ISMP Lists of						
Look-Alike Drug Names with Recommended Tall Man Letters (continued)						
	Table 1. FDA-Approved List of Generic Drug Names with Tall Man Letters (continued)					
Drug Name with Tall Man Letters	Confused with					
DOXOrubicin	DAUNOrubicin					
glipiZIDE	glyBURIDE					
glyBURIDE	glipiZIDE					
hydrALAZINE	hydrOXYzine					
hydrOXYzine	hydrALAZINE					
medroxyPROGESTERone	methylPREDNISolone - methylTESTOSTERone					
methylPREDNISolone	medroxyPROGESTERone - methyITESTOSTERone					
methyITESTOSTERone	medroxyPROGESTERone - methylPREDNISolone					
niCARdipine	NIFEdipine					
NIFEdipine	niCARdipine					
prednisoLONE	predniSONE					
predniSONE	prednisoLONE					
sulfADIAZINE	sulfiSOXAZOLE					
sulfiSOXAZOLE	sulfADIAZINE					
TOLAZamide	TOLBUTamide					
TOLBUTamide	TOLAZamide					
vinBLAStine	vinCRIStine					
vinCRIStine	vinBLAStine					

The list below is the sound alike look alike list approved for use in the Lake Physician Group Clinics as well as the LSU Health Baton Rouge Clinics.

Hum ULIN and Hum ALOG insulin				
Novol IN and Novol OG insulin				
Novol IN 70/30 and Novol OG mix				
AMARyl and REMINyl				
Avandia and Coumadin				
CeLEBREX, CeLEXA and CeREBYX				
clonazePAM (KlonoPIN) and CloNIDine (Catapres)				
LAntUS and LEntE Insulin				
Lami SIL and Lami CTAL				
ZyPREXA and ZyRTEC				
AdvICOR and AdvAIR				
DIAbeta and ZEbeta				
DiFLUCAN and DiPRIVAN				
PrILOSEC, PrOZAC and PrEVACID				
Wellbutrin SR and Wellbutrin XL				
Zantac, Zyrtec and Xyzal				
NEURONTIN and ZEURONTIN				
AvaLIDE and AvaPRO				
Rem ERON and RemINYL				

Policy Reference Number Page 4 of 5

FLOmax and FOSAmax				
SIMcor and SYMBIcor				
Heparin 10 units /ml and Heparin 10 0 units /ml				
MMR and MMRV (Proquad)				
Pneumococcal Conjugate Vaccine (Prevnar 13) and				
Pneumococcal Polysaccharide Vaccine (Pneumovax 23)				
Tdap and DTap or Td, Tb, DT				
PEDIArix and KINrix				
IPV and HPV				
Hib and Hep B				

Policy Reference Number Page 5 of 5